Published in J Biol Chem on April 29, 2011
Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis (2012) 1.72
HIV-1 transcription and latency: an update. Retrovirology (2013) 1.49
Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today (2012) 1.47
Combined approaches for HIV cure. Curr Opin HIV AIDS (2013) 1.23
Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J Biol Chem (2013) 1.17
Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother (2013) 1.12
From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. Bioessays (2013) 1.07
Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog (2013) 1.04
HIV-1 Vpr modulates macrophage metabolic pathways: a SILAC-based quantitative analysis. PLoS One (2013) 1.01
Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis (2013) 0.99
Epigenetic control of HIV-1 post integration latency: implications for therapy. Clin Epigenetics (2015) 0.98
From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology. Am J Physiol Cell Physiol (2014) 0.96
Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother (2012) 0.95
Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One (2014) 0.92
Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors. Antivir Chem Chemother (2014) 0.92
Negative elongation factor (NELF) coordinates RNA polymerase II pausing, premature termination, and chromatin remodeling to regulate HIV transcription. J Biol Chem (2013) 0.92
Regulation of immune responses by histone deacetylase inhibitors. ISRN Hematol (2012) 0.90
Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly. PLoS One (2013) 0.89
HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses (2014) 0.89
Structural insight into the separate roles of inositol tetraphosphate and deacetylase-activating domain in activation of histone deacetylase 3. Protein Sci (2012) 0.88
Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells. J Antimicrob Chemother (2013) 0.85
Class I and IIa histone deacetylases have opposite effects on sclerostin gene regulation. J Biol Chem (2014) 0.83
Oxamflatin treatment enhances cloned porcine embryo development and nuclear reprogramming. Cell Reprogram (2014) 0.82
Feline immunodeficiency virus latency. Retrovirology (2013) 0.81
Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB. PLoS One (2012) 0.81
Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1. PLoS One (2014) 0.80
Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL. Oncogenesis (2014) 0.79
A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression. Oncotarget (2014) 0.79
Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells. Biomed Res Int (2014) 0.79
Dissecting the mechanism of histone deacetylase inhibitors to enhance the activity of zinc finger nucleases delivered by integrase-defective lentiviral vectors. Hum Gene Ther (2014) 0.79
HIV-1 Vpr reactivates latent HIV-1 provirus by inducing depletion of class I HDACs on chromatin. Sci Rep (2016) 0.78
Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group. Medchemcomm (2015) 0.78
Study of marine natural products including resorcyclic acid lactones from Humicola fuscoatra that reactivate latent HIV-1 expression in an in vitro model of central memory CD4+ T cells. J Nat Prod (2014) 0.78
Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections. Antimicrob Agents Chemother (2015) 0.78
Transcriptional Gene Silencing (TGS) via the RNAi Machinery in HIV-1 Infections. Biology (Basel) (2012) 0.77
Interaction between endogenous bacterial flora and latent HIV infection. Clin Vaccine Immunol (2013) 0.77
The Impact of External Factors on the Epigenome: In Utero and over Lifetime. Biomed Res Int (2016) 0.77
Class IIa histone deacetylases affect neuronal remodeling and functional outcome after stroke. Neurochem Int (2016) 0.76
Impact of Chromatin on HIV Replication. Genes (Basel) (2015) 0.75
AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3. Oncotarget (2015) 0.75
Inactivating mutation in histone deacetylase 3 stabilizes its active conformation. Protein Sci (2013) 0.75
Quiescence promotes latent HIV infection and resistance to reactivation from latency with histone deacetylase inhibitors. J Virol (2017) 0.75
Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. Sci Rep (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet (2009) 9.68
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol (2001) 4.92
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses (2009) 4.32
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem (2009) 3.71
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.66
The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol (2000) 3.43
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science (2010) 3.29
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS (2004) 3.17
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J (2007) 2.74
HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med (2010) 2.71
Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol (2002) 2.64
A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30
Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS (2009) 2.28
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol (1998) 2.23
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20
CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J (2007) 2.20
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One (2010) 2.09
A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Proc Natl Acad Sci U S A (1996) 2.06
Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem (2006) 1.73
Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses (2009) 1.66
"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology (2009) 1.59
NF-kappa B-dependent and -independent pathways of HIV activation in a chronically infected T cell line. Virology (1994) 1.47
Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep (2010) 1.33
Induction of chromosomally integrated HIV-1 LTR requires RBF-2 (USF/TFII-I) and Ras/MAPK signaling. Virus Genes (2007) 1.11
Histone deacetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines. Int J Mol Med (2010) 1.04
Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther (2010) 1.03
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol (2005) 7.91
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 4.82
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS (2009) 2.91
Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One (2007) 2.84
Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS (2006) 2.71
Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr (2002) 2.70
Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA (2007) 2.59
Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr (2010) 2.46
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol (2006) 2.45
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med (2007) 2.41
Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol (2003) 2.32
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. J Infect Dis (2010) 2.15
Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci U S A (2011) 1.93
Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS (2008) 1.91
In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother (2005) 1.83
Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci U S A (2005) 1.79
Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa. J Infect Dis (2013) 1.77
Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa. AIDS Res Treat (2010) 1.75
The need for treatment interruption studies and biomarker identification in the search for an HIV cure. AIDS (2015) 1.68
Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr (2006) 1.62
The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. AIDS (2006) 1.60
The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol (2006) 1.59
Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. J Virol (2007) 1.57
HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol (2010) 1.57
Genetic correlates of efavirenz hypersusceptibility. AIDS (2004) 1.50
Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS (2007) 1.47
Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA. Retrovirology (2013) 1.45
Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A (2011) 1.42
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 1.39
Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol Pharmacol (2007) 1.38
Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med (2015) 1.37
Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2006) 1.37
Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc (2010) 1.35
Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr (2013) 1.34
The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. J Biol Chem (2005) 1.30
Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol (2007) 1.30
Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis (2006) 1.29
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis (2009) 1.28
Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP). PLoS One (2011) 1.26
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis (2013) 1.26
Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS Pathog (2006) 1.25
Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2002) 1.25
The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS (2016) 1.25
Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS (2013) 1.24
YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol (2008) 1.23
Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. J Virol (2010) 1.21
Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin Infect Dis (2011) 1.18
HIV populations are large and accumulate high genetic diversity in a nonlinear fashion. J Virol (2013) 1.17
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis (2012) 1.17
Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Sci (2007) 1.16
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA (2006) 1.14
Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones. J Biol Chem (2001) 1.11
Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clin Infect Dis (2012) 1.11
Multiple sources of contamination in samples from patients reported to have XMRV infection. PLoS One (2012) 1.08
Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design. J Virol Methods (2009) 1.08
New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond. Curr HIV/AIDS Rep (2012) 1.08
Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob Agents Chemother (2007) 1.07
Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. Biochem J (2007) 1.05
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS (2010) 1.05
Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. FEBS Lett (2005) 1.05
Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. AIDS (2006) 1.04
Loss of cathepsin L activity promotes claudin-1 overexpression and intestinal neoplasia. FASEB J (2007) 1.04
Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay. Retrovirology (2013) 1.03
Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants. J Clin Microbiol (2005) 1.03
Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry (2008) 1.02
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS (2003) 1.02
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS (2005) 1.01
In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine. Antimicrob Agents Chemother (2005) 0.99
Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. AIDS (2004) 0.99
Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). PLoS One (2013) 0.99
Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. Antivir Ther (2011) 0.97
Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. Clin Infect Dis (2013) 0.96
Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir Ther (2009) 0.96
The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs. J Virol (2009) 0.95
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med (2009) 0.93
Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency. AIDS (2008) 0.92
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. Antimicrob Agents Chemother (2009) 0.91
Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. Antivir Ther (2012) 0.90
A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther (2003) 0.90